Plain-English translation of NCT03648814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Neovascular glaucoma is a serious eye condition where abnormal blood vessels grow in the eye and raise eye pressure dangerously high. This trial is testing bevacizumab, a medication that stops these abnormal blood vessels from growing. The study compares two ways of injecting this medication—directly into the eye's front chamber versus deeper into the eye—to see which method works better and is safer when used before surgery.
Doctors know that this medication can help control neovascular glaucoma before surgery, but they're not sure which injection method gives patients the best results with the fewest side effects. This trial will help answer that question.
You likely qualify if…
You likely don't qualify if…
You will receive one injection of the medication before your scheduled glaucoma surgery. The study will randomly assign you to receive the injection either in the front chamber of your eye or deeper inside the eye. You will then have follow-up visits to check how well the treatment worked, how your eye heals after surgery, and to watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Thailand
Sponsor
Prince of Songkla University
Enrollment target
~40 participants
Started
August 2018
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Assoc.Prof.Weerawat Kiddee, MD
Prince of Songkla University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.